Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Cagrilintide and Semaglutide have evidence — compare verdict strength side-by-side.
Investigational — NO approved monotherapy dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.5 mg maintenance. There is no approved standalone regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Over 26 weeks
Over 20-32 weeks
By 32 weeks
Especially during dose escalation
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet (2021) · Rct · n=706
Phase-2, double-blind, randomised, placebo- and active-controlled dose-finding trial across 57 sites in ten countries; 706 adults with overweight/obesity (no diabetes) on once-weekly subcutaneous cagrilintide 0.3-4.5 mg vs liraglutide 3.0 mg vs placebo over 26 weeks
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet (2021) · Rct · n=95
Phase-1b, randomised, placebo-controlled, multiple-ascending-dose trial in 95 treated adults with overweight/obesity; once-weekly subcutaneous cagrilintide 0.16-4.5 mg co-administered with semaglutide 2.4 mg over 20 weeks
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet (2023) · Rct · n=92
Phase-2, double-blind, active-controlled trial in 92 adults with type 2 diabetes on metformin ± SGLT2 inhibitor; once-weekly CagriSema vs semaglutide vs cagrilintide (all escalated to 2.4 mg) over 32 weeks
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
No known interactions between Cagrilintide and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.